Double maintains 2 strategies that include SDGR - Schrödinger, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 65.48% | $1.05B | 0.75% |
GNOM | 59.13% | $44.43M | 0.5% |
XBI | 53.79% | $4.95B | 0.35% |
IWO | 52.77% | $11.48B | 0.24% |
IWC | 52.29% | $824.65M | 0.6% |
PTH | 52.19% | $101.07M | 0.6% |
KJUL | 51.25% | $120.75M | 0.79% |
ISCG | 50.84% | $679.06M | 0.06% |
KOMP | 50.43% | $2.28B | 0.2% |
IWMY | 50.39% | $118.33M | 1.02% |
IBB | 50.23% | $5.36B | 0.45% |
IWM | 50.21% | $64.00B | 0.19% |
VTWO | 50.21% | $13.29B | 0.07% |
VBK | 50.01% | $18.97B | 0.07% |
VXF | 49.51% | $22.24B | 0.05% |
SCHA | 49.12% | $17.26B | 0.04% |
PBE | 49.04% | $223.24M | 0.58% |
FINX | 49.03% | $309.82M | 0.68% |
NUSC | 48.94% | $1.13B | 0.31% |
QQQJ | 48.90% | $617.03M | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ED | -17.99% | $35.36B | +9.76% | 3.39% |
CBOE | -15.91% | $23.98B | +34.66% | 1.10% |
SO | -11.23% | $99.90B | +17.18% | 3.20% |
AEP | -11.21% | $54.73B | +16.78% | 3.58% |
EXC | -10.63% | $43.32B | +23.98% | 3.65% |
VZ | -10.40% | $178.39B | +2.59% | 6.38% |
T | -10.08% | $202.05B | +46.94% | 3.95% |
AWK | -9.98% | $26.90B | +6.78% | 2.27% |
CME | -9.74% | $99.01B | +39.76% | 3.87% |
NEE | -9.66% | $145.94B | +0.11% | 3.18% |
MO | -9.34% | $98.96B | +28.98% | 6.98% |
VOD | -9.07% | $25.87B | +18.94% | 4.63% |
AMT | -8.22% | $101.95B | +12.04% | 3.05% |
CMS | -7.87% | $20.64B | +15.92% | 3.07% |
TEF | -7.72% | $29.29B | +23.28% | 6.30% |
ZCMD | -7.60% | $28.79M | -13.64% | 0.00% |
K | -7.40% | $27.41B | +36.96% | 2.88% |
DUK | -6.20% | $90.88B | +16.65% | 3.59% |
WEC | -5.77% | $32.91B | +31.44% | 3.35% |
CCI | -5.74% | $43.83B | +3.02% | 5.73% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CERT | 63.96% | $1.85B | -17.83% | 0.00% |
SLP | 60.58% | $339.07M | -65.32% | 0.35% |
ABCL | 56.15% | $1.08B | +21.96% | 0.00% |
RXRX | 55.31% | $2.04B | -32.93% | 0.00% |
CRSP | 51.99% | $4.10B | -12.07% | 0.00% |
NTLA | 48.90% | $990.25M | -57.28% | 0.00% |
BEAM | 48.87% | $1.69B | -28.30% | 0.00% |
TWST | 47.16% | $2.15B | -27.09% | 0.00% |
RGEN | 46.18% | $6.94B | -1.98% | 0.00% |
DNA | 46.09% | $525.33M | -29.26% | 0.00% |
BIO | 45.75% | $6.64B | -10.67% | 0.00% |
DNLI | 45.52% | $2.05B | -39.28% | 0.00% |
GH | 44.96% | $6.30B | +76.11% | 0.00% |
ITT | 44.69% | $12.43B | +22.27% | 0.85% |
PHR | 44.42% | $1.70B | +34.39% | 0.00% |
TXG | 44.36% | $1.46B | -39.69% | 0.00% |
CYRX | 43.90% | $371.52M | +7.24% | 0.00% |
IQV | 43.86% | $27.24B | -25.53% | 0.00% |
SNPS | 43.42% | $77.99B | -15.53% | 0.00% |
FTV | 43.37% | $18.33B | -3.37% | 0.61% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IGSB | 0.01% | $21.60B | 0.04% |
BWX | 0.03% | $1.53B | 0.35% |
SPSK | -0.04% | $316.15M | 0.5% |
PULS | 0.04% | $11.69B | 0.15% |
BNDX | 0.08% | $67.37B | 0.07% |
BILZ | 0.12% | $827.49M | 0.14% |
IBDR | 0.15% | $3.33B | 0.1% |
CANE | 0.17% | $10.44M | 0.29% |
IBDV | 0.17% | $1.89B | 0.1% |
UDN | 0.26% | $147.88M | 0.78% |
BSCP | -0.29% | $3.28B | 0.1% |
PYLD | 0.32% | $5.82B | 0.69% |
IBDQ | 0.36% | $2.99B | 0.1% |
BSCR | 0.36% | $3.66B | 0.1% |
BLV | 0.37% | $5.70B | 0.03% |
VCSH | 0.41% | $34.31B | 0.03% |
BGRN | 0.42% | $403.39M | 0.2% |
NUAG | 0.44% | $58.72M | 0.19% |
JUCY | -0.46% | $271.76M | 0.6% |
HYMB | -0.47% | $2.62B | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -41.70% | $296.79M | 1.43% |
TAIL | -39.82% | $99.76M | 0.59% |
VIXY | -39.51% | $165.69M | 0.85% |
XONE | -25.39% | $585.86M | 0.03% |
SHYM | -23.87% | $350.04M | 0.35% |
SPTS | -21.49% | $5.78B | 0.03% |
AGZ | -20.32% | $614.02M | 0.2% |
ULST | -19.53% | $662.59M | 0.2% |
IVOL | -18.88% | $349.27M | 1.02% |
VGSH | -18.47% | $22.80B | 0.03% |
CGSM | -18.43% | $710.40M | 0.25% |
UTWO | -17.80% | $379.36M | 0.15% |
BSMW | -17.59% | $107.26M | 0.18% |
IBTH | -16.98% | $1.60B | 0.07% |
SCHO | -16.83% | $11.46B | 0.03% |
IBTG | -16.25% | $1.92B | 0.07% |
IBTJ | -16.13% | $685.71M | 0.07% |
STXT | -15.87% | $129.73M | 0.49% |
IEI | -15.74% | $15.37B | 0.15% |
IBTI | -15.50% | $1.06B | 0.07% |
Current Value
$20.001 Year Return
Current Value
$20.001 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CIG.C | -0.04% | $2.64B | +19.84% | 0.00% |
FENG | 0.32% | $11.56M | -21.03% | 0.00% |
EQNR | -0.35% | $68.66B | -8.28% | 5.67% |
COR | 0.36% | $58.03B | +32.90% | 0.72% |
CI | -0.45% | $87.17B | -1.29% | 1.78% |
SBAC | 0.45% | $24.80B | +17.58% | 1.81% |
EDU | 0.50% | $8.85B | -29.65% | 0.00% |
PPL | 0.59% | $24.81B | +21.37% | 3.18% |
CYCN | -0.62% | $9.63M | +30.43% | 0.00% |
PEP | -0.63% | $179.67B | -20.55% | 4.19% |
CWEN | -0.67% | $3.79B | +30.17% | 5.36% |
PG | 0.70% | $374.80B | -3.07% | 2.56% |
DG | 0.91% | $25.19B | -13.45% | 2.07% |
MSEX | -0.93% | $976.83M | +4.31% | 2.48% |
CWEN.A | -0.96% | $3.59B | +34.47% | 5.70% |
JNJ | 1.00% | $366.71B | +4.28% | 3.30% |
WTRG | -1.03% | $10.35B | -1.10% | 3.50% |
PGR | 1.10% | $154.76B | +27.10% | 1.86% |
DFDV | 1.16% | $247.94M | +1,821.34% | 0.00% |
ES | -1.17% | $23.28B | +11.73% | 4.65% |
Finnhub
NEW YORK - Schrodinger, Inc. today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration for the treatment of...
Yahoo
NEW YORK, June 27, 2025--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Finnhub
Schrodinger, Inc. announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration for the treatment of adult patients with...
Finnhub
By Colin Kellaher Schrodinger has won U.S. Food and Drug Administration fast-track designation for its SGR-1505 drug candidate in a rare type of non-Hodgkin's lymphoma. Schrodinger on Friday...
Finnhub
NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
NEW YORK - Schrodinger, Inc. reported that on June 13, 2025, the company granted restricted stock units with respect to 10,290 shares of the company's common stock to five newly hired...